Please login to the form below

Not currently logged in

Boehringer to research cause of diabetes with German university

Five-year collaboration with TU Dresden will also look at link between high blood sugar levels and diabetes complications

Boehringer Ingelheim has signed a pact with the Technische Universität (TU) in Dresden to research the cause of type 1 diabetes.

The German pharma firm said results from a range of planned studies may help to design new medicines and improve understanding of how diabetes drugs can be made into more personalised medicines.

Boehringer will work with the university's department of medicine and GWT, a private R&D company based within TU Dresden, in a five-year collaboration that will also look at the link between high blood sugar and complications associated with diabetes.

The research partners will focus on six projects that cover preclinical findings and investigational treatments and how they translate to clinical situations with patients.

These projects include research into the destruction of insulin-producing beta cells - the genetic cause of type 1 diabetes - for which a reason is still unknown.

Further research will look at the molecular reasons behind diabetic complications in parts of the body like eyes, kidneys, nerves and skin.

The collaboration has a similar purpose as Novo Nordisk's planned type 1 diabetes research centre in Seattle, US.

This will also take a translational approach, combining basic research and early proof-of-concept trials to ensure investigations can develop quickly from animal models into exploratory trials.

The moves follow a trend to more research into type 1 diabetes, incidents of which are growing alongside type 2 diabetes, but for less certain reasons.

It is estimated that 366m people currently live with either form of the condition worldwide, according to the International Diabetes Federation (IDF), with 78,000 children developing type 1 diabetes every year.

Other firms to increase research efforts into the condition include Sanofi, which is also collaborating with an academic institution after signing a $3.1m alliance with the University of California.

6th February 2012


Featured jobs

Subscribe to our email news alerts


Add my company
Serviceplan Health & Life

We are your creative global lead agency, your Pan-European hub and your worldwide network....

Latest intelligence

White paper download: Creating experiences to improve patient outcomes
Download our white paper "Creating experiences to improve patient outcomes" to learn the steps to building an effective customer experience strategy....
Organisational Memory
In a knowledge-based industry with high labour mobility, retaining that knowledge within an organisation during a drug’s lifecycle can be tricky. If we undervalue the knowledge, experience and marketing understanding...
Thoughts on the intersection between technology and psychology
Paul Mannu - Master Practitioner, Behavioural Insights at Cello Health Insight gives us his succinct thoughts on the intersection between technology and psychology...